Advertisement

The time has come to standardize 123I-MIBG heart-to-mediastinum ratios including planar and SPECT methods

  • Kenichi NakajimaEmail author
  • Koichi Okuda
  • Shinro Matsuo
  • Denis Agostini
Letter to the Editor

Dear Sir,

Bellevre et al. used D-SPECT (Spectrum Dynamics, Israel) with a cadmium zinc telluride-based camera for the determination of the heart-to-mediastinum ratio (HMR) of myocardial 123I-metaiodobenzylguanidine (MIBG) uptake [1]. Since some institutions have changed their SPECT equipment from Anger SPECT to D-SPECT for cardiac studies, conventional planar images are not available in the routine clinical setting. Although the European Association of Nuclear Medicine (EANM) Cardiovascular Committee and the European Council of Nuclear Cardiology have recommended the use of medium-energy (ME) collimators for 123I-MIBG studies [2], a number of hospitals still use low-energy (LE) collimators, and SPECT MIBG HMRs have been added recently.

While the 123I-MIBG study has been widely used to patients with chronic heart failure and Lewy body disease, most studies have used planar HMR [3, 4, 5]. Whether we can still use the previous numerous stock of data and how we can connect the follow-up...

Keywords

Nuclear Cardiology European Council Conversion Coefficient Lewy Body Disease Cadmium Zinc 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Compliance with ethical standards

Conflicts of interest

K.N. has a collaborative research work for development of the software with FUJIFILM RI Pharma, Co. Ltd, Japan, supplier of 123I-MIBG (MyoMIBG) in Japan. The other authors declare no conflicts of interest.

References

  1. 1.
    Bellevre D, Manrique A, Legallois D, Bross S, Baavour R, Roth N, et al. First determination of the heart-to-mediastinum ratio using cardiac dual isotope (123I-MIBG/99mTc-tetrofosmin) CZT imaging in patients with heart failure: the ADRECARD study. Eur J Nucl Med Mol Imaging. 2015;42:1912–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Flotats A, Carrio I, Agostini D, Le Guludec D, Marcassa C, Schafers M, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802–12.PubMedCrossRefGoogle Scholar
  3. 3.
    Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al. A pooled analysis of multicenter cohort studies of 123I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging. 2013;6:772–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Verschure DO, Veltman CE, Manrique A, Somsen GA, Koutelou M, Katsikis A, et al. For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic heart failure? Results of a pooled individual patient data meta-analysis. Eur Heart J Cardiovasc Imaging. 2014;15:996–1003.PubMedCrossRefGoogle Scholar
  6. 6.
    Nakajima K, Okuda K, Matsuo S, Yoshita M, Taki J, Yamada M, et al. Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging. 2012;39:113–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Nakajima K, Okuda K, Yoshimura M, Matsuo S, Wakabayashi H, Imanishi Y, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol. 2014;21:970–8.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Nakajima K, Nakata T, Yamada T, Yamashina S, Momose M, Kasama S, et al. A prediction model for 5-year cardiac mortality in patients with chronic heart failure using 123I-metaiodobenzylguanidine imaging. Eur J Nucl Med Mol Imaging. 2014;41:1673–82.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Kenichi Nakajima
    • 1
    Email author
  • Koichi Okuda
    • 2
  • Shinro Matsuo
    • 1
  • Denis Agostini
    • 3
  1. 1.Department of Nuclear MedicineKanazawa University HospitalKanazawaJapan
  2. 2.Department of PhysicsKanazawa Medical UniversityUchinadaJapan
  3. 3.Department of Nuclear Medicine, CHU Côte de NacreNormandy University EA 4650CaenFrance

Personalised recommendations